Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …

Introduction: The impact of vaccination and casirivimab-imdevimab monoclonal antibody
treatment on the clinical outcome of COVID-19 during a period of SARS-CoV-2 Delta surge …

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS+ IMD) …

Objective To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent
for treating coronavirus 2019 (COVID-19). Methods A retrospective cohort study was …